Inoue Toshihiro

Asaoka Ryo, Sugisaki Kenji, Inoue Toshihiro, Yoshikawa Keiji, Kanamori Akiyasu, Yamazaki Yoshio et al.

This study found that 24-2 visual field results in advanced glaucoma can be reasonably predicted from 10-2 test results, useful when 24-2 data is unavailable.

Asaoka Ryo, Sugisaki Kenji, Inoue Toshihiro, Yoshikawa Keiji, Kanamori Akiyasu, Yamazaki Yoshio et al.

This study found that poorer central vision sensitivity in the temporal papillomacular bundle (HFA 10-2) in advanced glaucoma predicts future visual acuity decline, guiding closer monitoring for vision loss risk.

Irie Anna, Nakashima Kei-Ichi, Inoue Toshihiro, Kojima Sachi, Takihara Yuji, Takahashi Eri

KDB trabeculotomy with a 210-240-degree incision provided better IOP lowering than a 120-degree incision, especially in exfoliation glaucoma, suggesting larger incisions improve surgical success.

Murata Natsumi, Takahashi Eri, Saruwatari Junji, Kojima Sachi, Inoue Toshihiro

KDB-LOT effectively lowered IOP in diverse glaucoma types, but rarely below 15 mmHg. Age and combined phacoemulsification improved outcomes, guiding surgical selection for this moderate IOP-lowering procedure.

Nakamura Kenichi, Fujimoto Tomokazu, Okada Miho, Maki Kentaro, Shimazaki Atsushi, Kato Masatomo et al.

Rabbit studies showed SIBS and silicone glaucoma drainage device materials were more biostable and caused less tissue reactivity than GACLC, suggesting better clinical safety.

Sugisaki Kenji, Inoue Toshihiro, Yoshikawa Keiji, Kanamori Akiyasu, Yamazaki Yoshio, Ishikawa Shinichiro et al.

This 5-year study found that in advanced glaucoma, baseline vision, peripapillary atrophy, and systemic antihypertensive use predict further central visual decline, even with controlled IOP, guiding closer monitoring.

Kusano Yuki, Yamaguchi Takefumi, Nishisako Sota, Matsumura Takehiro, Fukui Masaki, Higa Kazunari et al.

This study found high preoperative aqueous protein and specific cytokine levels predict peripheral anterior synechiae progression after DSAEK, indicating chronic inflammation contributes to glaucoma risk.

Fujimoto Tomokazu, Nakashima Kei-Ichi, Watanabe-Kitamura Fumika, Watanabe Takahiro, Nakamura Kenichi, Maki Kentaro et al.

This rabbit study found MicroShunt insertion lowered IOP similarly to trabeculectomy, suggesting comparable efficacy for glaucoma treatment.

Kiyama Yu, Nakashima Kei-Ichi, Inoue Toshihiro

A glaucoma patient developed conjunctival laceration after MP-CPC, likely due to pre-existing subconjunctival hemorrhage. Clinically, exercise caution with MP-CPC in eyes with significant subconjunctival hemorrhage.

Sugisaki Kenji, Asaoka Ryo, Inoue Toshihiro, Yoshikawa Keiji, Kanamori Akiyasu, Yamazaki Yoshio et al.

This study found that machine learning (SVR) can predict central 10-2 visual fields from 24-2 fields in advanced glaucoma with about 25% error, aiding central vision assessment.

Yamagishi-Kimura Reiko, Honjo Megumi, Komizo Takashi, Ono Takashi, Yagi Akiko, Lee Jinhee et al.

This study found pilocarpine interfered with ripasudil's IOP-lowering effects by altering outflow pathway cells. Clinically, combining these glaucoma drugs may reduce ripasudil's efficacy.

Futakuchi Akiko, Inoue Toshihiro, Fujimoto Tomokazu, Kuroda Utako, Inoue-Mochita Miyuki, Takahashi Eri et al.

SAHA inhibits conjunctival fibroblast activation and angiogenesis by modulating TGF-β signaling, explaining its potential to prevent scarring and maintain blebs after glaucoma surgery.

Tsutsumi Takayuki, Iwao Keiichiro, Hayashi Hideki, Kirihara Tomoko, Kawaji Takahiro, Inoue Toshihiro et al.

This study found the LSD1 inhibitor tranylcypromine protected retinal ganglion cells from damage by activating p38 MAPKγ, suggesting a novel neuroprotective glaucoma therapy.

Matsumura Riyo, Inoue Toshihiro, Tanihara Hidenobu

AS-OCT and pathology revealed a bleb-like structure in an absolute glaucoma eye was idiopathic scleral thinning, not a surgical bleb. This highlights diagnostic challenges in atypical presentations.

Tanihara Hidenobu, Inoue Toshihiro, Yamamoto Tetsuya, Kuwayama Yasuaki, Abe Haruki, Fukushima Atsuki et al.

Ripasudil (0.4%) effectively lowered intraocular pressure for one year in glaucoma/OHT patients, alone or with other drugs, with conjunctival hyperemia as a common, usually mild side effect.

Tanihara Hidenobu, Inoue Toshihiro, Yamamoto Tetsuya, Kuwayama Yasuaki, Abe Haruki, Suganami Hideki et al.

Ripasudil combined with timolol or latanoprost showed additive IOP-lowering effects, particularly at peak, offering a safe, new treatment option for glaucoma patients needing further pressure reduction.

Ohira Saori, Inoue Toshihiro, Shobayashi Kohei, Iwao Keiichiro, Fukushima Mikiko, Tanihara Hidenobu

Neovascular glaucoma patients show elevated pro-inflammatory cytokines. While bevacizumab reduces VEGF, other inflammatory markers persist, highlighting ongoing inflammation in NVG.

Inoue Toshihiro, Tanihara Hidenobu, Tokushige Hideki, Araie Makoto

Kojima Sachi, Inoue Toshihiro, Nakashima Kei-Ichi, Fukushima Ayako, Tanihara Hidenobu

This study found early bleb filtration opening width, measured by 3D-OCT post-trabeculectomy, correlates with long-term IOP control, suggesting it's a prognostic factor for surgical success.

Tanihara Hidenobu, Inoue Toshihiro, Yamamoto Tetsuya, Kuwayama Yasuaki, Abe Haruki, Suganami Hideki et al.

Ripasudil effectively lowered intraocular pressure for at least 7 hours in glaucoma/ocular hypertension patients, demonstrating its promise as a new topical treatment.

Nakashima Kei-Ichi, Inoue Toshihiro, Fukushima Ayako, Hirakawa Saori, Kojima Sachi, Tanihara Hidenobu

This study found that glaucoma filtering blebs with transconjunctival oozing, often linked to lower IOP, are characterized by increased height, thicker/less dense walls, and reduced vascularity.

Inoue Toshihiro, Kawaji Takahiro, Tanihara Hidenobu

Aqueous humor MCP-1 levels were studied in glaucoma patients undergoing trabeculectomy. High MCP-1 predicted poorer surgical success, suggesting it could guide prognosis and treatment planning.

Inoue Toshihiro, Tanihara Hidenobu

ROCK inhibitors enhance aqueous outflow by modulating trabecular meshwork and Schlemm's canal, potentially offering a novel glaucoma treatment with neuroprotective and blood flow benefits.

Tanihara Hidenobu, Inoue Toshihiro, Yamamoto Tetsuya, Kuwayama Yasuaki, Abe Haruki, Araie Makoto

Phase 1 trials of K-115, a Rho kinase inhibitor, showed it safely and effectively lowered intraocular pressure in healthy volunteers, indicating promise for glaucoma treatment despite mild, transient redness.

Tanihara Hidenobu, Inoue Toshihiro, Yamamoto Tetsuya, Kuwayama Yasuaki, Abe Haruki, Araie Makoto

K-115, a Rho kinase inhibitor, significantly lowered IOP in glaucoma/ocular hypertension patients dose-dependently, with 0.4% being optimal. This offers a promising new treatment for 24-hour IOP control.